An updated estimate of the proportion of neurocysticercosis among people with epileptic seizures: a systematic review and Bayesian meta-analysis.

Infect Dis PovertySep 10, 2026 (epub)
Clinical ResearchNeurologyInfectious DiseasesOpen access

Mohammad Shah Jalal, Orane Figuet, Katrina Di Bacco et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and Bayesian meta-analysis estimated the pooled proportion of neurocysticercosis (NCC) among people with epileptic seizures (PWES) from 1990 to 2023. The analysis included 77 studies, revealing a pooled NCC proportion of 25.2% (95% BCI: 19.5%-32.2%). Notably, the proportion declined in endemic regions from June 2008 to May 2023.

Key findings

  • The pooled proportion of NCC among PWES was 25.2% (95% BCI: 19.5%-32.2%).
  • NCC proportion did not vary by sex or age among PWES.
  • A decline in NCC proportion was observed from June 2008 to May 2023 across multiple regions.

Why it matters

Understanding the prevalence of neurocysticercosis among individuals with epileptic seizures is crucial for public health planning and resource allocation in endemic regions. The observed decline may indicate improvements in diagnosis or control measures.

Source

PubMed · PMID 42717381Free full text on PubMed Central

Published in Infect Dis Poverty. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.